Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

73
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
73
Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

113
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
113
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

70
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
70
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

76
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
76
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

68
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
68
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

97
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
97

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultrastructural changes in cryopreserved tracheal grafts of sprague-dawley rats.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2009
Same author

Facile synthesis of size-tunable micro-octahedra via metal-organic coordination.

Chemical communications (Cambridge, England)·2009
Same author

N-acetyl cysteine and penicillamine induce apoptosis via the ER stress response-signaling pathway.

Molecular carcinogenesis·2009
Same author

Targeting glucosylceramide synthase downregulates expression of the multidrug resistance gene MDR1 and sensitizes breast carcinoma cells to anticancer drugs.

Breast cancer research and treatment·2009
Same author

N-glycosylation of ATF6beta is essential for its proteolytic cleavage and transcriptional repressor function to ATF6alpha.

Journal of cellular biochemistry·2009
Same author

A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo.

Cancer immunology, immunotherapy : CII·2009

Related Experiment Video

Updated: Mar 14, 2026

Synthesis of Gold Nanoparticle Integrated Photo-responsive Liposomes and Measurement of Their Microbubble Cavitation upon Pulse Laser Excitation
12:00

Synthesis of Gold Nanoparticle Integrated Photo-responsive Liposomes and Measurement of Their Microbubble Cavitation upon Pulse Laser Excitation

Published on: February 24, 2016

8.6K

pH-Responsive drug release and NIR-triggered singlet oxygen generation based on a multifunctional core-shell-shell

Renlu Han1, Haopeng Yi1, Junhui Shi1

  • 1School of Materials Science and Engineering, Harbin Institute of Technology, Harbin 150001, People's Republic of China. y-wang@hit.edu.cn.

Physical Chemistry Chemical Physics : PCCP
|October 7, 2016
PubMed
Summary

This study presents a novel nanoplatform for pH-responsive chemotherapy and near-infrared light-activated photodynamic therapy (PDT). The system effectively releases drugs in acidic conditions and generates therapeutic reactive oxygen species for cancer treatment.

More Related Videos

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform
06:27

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Published on: October 20, 2020

5.7K
Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
08:54

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

Published on: February 17, 2023

1.6K

Related Experiment Videos

Last Updated: Mar 14, 2026

Synthesis of Gold Nanoparticle Integrated Photo-responsive Liposomes and Measurement of Their Microbubble Cavitation upon Pulse Laser Excitation
12:00

Synthesis of Gold Nanoparticle Integrated Photo-responsive Liposomes and Measurement of Their Microbubble Cavitation upon Pulse Laser Excitation

Published on: February 24, 2016

8.6K
Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform
06:27

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Published on: October 20, 2020

5.7K
Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
08:54

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies

Published on: February 17, 2023

1.6K

Area of Science:

  • Nanomedicine
  • Materials Science
  • Biomedical Engineering

Background:

  • Developing multifunctional nanocarriers is crucial for advanced cancer therapy.
  • Combining chemotherapy with photodynamic therapy (PDT) offers synergistic treatment potential.

Purpose of the Study:

  • To design and synthesize a core-shell-shell nanoplatform integrating pH-responsive drug release and upconversion nanoparticle-based PDT.
  • To evaluate the drug release kinetics and PDT efficacy of the developed system.

Main Methods:

  • Fabrication of a core-shell-shell structure using upconversion nanoparticles, silica, methylene blue, polyethyleneimine-folic acid, and doxorubicin hydrochloride.
  • In vitro evaluation of pH-responsive drug release under simulated acidic conditions.
  • Assessment of PDT efficacy upon near-infrared (NIR) irradiation.

Main Results:

  • The nanoplatform demonstrated controlled release of doxorubicin hydrochloride in acidic environments.
  • NIR irradiation triggered methylene blue to generate singlet oxygen for PDT.
  • The integrated system showed potential for combined chemotherapy and PDT.

Conclusions:

  • The novel core-shell-shell nanoplatform effectively combines pH-responsive chemotherapy with NIR-triggered PDT.
  • This multifunctional system holds significant promise for advanced nanomedicine applications in cancer treatment.